Published
2025-01-14
Section
Articles
How to Cite
肺癌靶向药物的研发与临床应用
包 晨
内蒙古医科大学通辽临床医学院
DOI: https://doi.org/10.59429/xjjz.v6i4.8615
Keywords: 非小细胞肺癌；精准医疗；靶向治疗；EGFR 突变；耐药机制
Abstract
非小细胞肺癌（NSCLC）是最常见的肺癌类型，驱动基因突变的精准治疗显著改善了患者的生存期和生活质量。 EGFR、ALK 和 KRAS 等驱动基因的靶向药物，如埃克替尼、克唑替尼和 Sotorasib，在临床应用中表现出较好疗效， 但治疗耐药性和肿瘤异质性仍是主要挑战。研究发现，T790M 突变、旁路激活等机制是靶向治疗耐药的主要原因。 为克服耐药问题，新一代 TKI 药物、靶向与免疫联合治疗成为重要策略。未来，通过液体活检、二代测序等分子诊 断技术，以及大数据与人工智能支持的个性化医疗，可进一步提高 NSCLC 精准治疗效果，解决耐药性和异质性问题， 推动肺癌治疗向更精准、个体化方向发展。
References
[1] 石亚飞,陈伟,曹宇,等.非小细胞肺癌患者预后影响因素分析及预测列线图构建[J].中国医院药学杂志,2018,38(20):52-55+88.
[2] 葛辰蕾,李醒亚,尚可,等.非小细胞肺癌预后影响因素分析[J].郑州大学学报(医学版),2011,46(2):58-61.
[3] 宋肖玲,屈小娟,曲思琪,等.靶向EGFR蛋白降解剂及其在非小细胞肺癌中的应用[J].自然杂志,2021,43(6):14-21.
[4] RITTER C A, ARTEAGA C L. The epidermal growth factor receptor-tyrosine kinase:a promising therapeutic target in solid tumors[J]. Semin Oncol,2003,30(S1):3-11.
[5] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases[J]. Cell,2010,141(7) :1117-1134.
[6] 王永生,周彩存.ALK抑制剂研究进展[J].中国医学前沿杂志(电子版),2018,10(7):50-55.
[7] Jin Y, Sun PL, Park SY, et al. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival[J]. Lung Cancer, 2015,89(3) :343-349.
[8] Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer[J]. Cancer Res,2012,72(10):2457-2467.
[9] 周晓荣.Kras基因突变的非小细胞肺癌靶向治疗进展[J].现代肿瘤医学,2015,23(9):127-130.
[10] 王洁,赫捷,王志杰,等.原发性肺癌罕见靶点靶向治疗中国临床诊疗指南(2024版)[J].中国肿瘤临床与康复,2024,31(5):5-35.
[11] 林慧娴,陈静.液体活检分析技术研究进展[J].临床检验杂志,2019,37(8):33-37.
[12] 周霄.中国非小细胞肺癌靶向治疗10年高端峰会在沪召开[J].康复,2015(4):9.
[13] Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med,2013,368(25) :2385-94.
[14] 包小云,吕庄,栾天燕,等.Sotorasib治疗KRAS G12C突变非小细胞肺癌53例分析[J].肿瘤学杂志,2024,30(9):23-27.
[15] SHEN Z, QIU B, LI L, et al. Targeted therapy of RET fusion_xfffe_positive non-small cell lung cancer[J]. Front Oncol,2022(12):1-13.
[16] GRIESINGER F, CURIGLIANO G, THOMAS M, et al. Safety and efficacy of pralsetinib in RET fusion–positive non-small_xfffe_cell lung cancer including as first-line therapy:Update from the ARROW trial[J]. Ann Oncol.
[17] 主要是在毛细胞白血病(100%)、黑色素瘤(50%)、甲状腺乳头状癌(45%)等疾病中[Z].
[18] Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med,2015,373(8) :726-736.
[19] HONG D S, DUBOIS S G, KUMMAR S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours:a pooled analysis of three phase 1/2 clinical trials[J]. Lancet Oncol,2020,21(4):531-540.
[20] Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer:5-year outcomes from the phase 3 KEYNOTE-189 study[J]. J Clin Oncol,2023(41).
[21] 韩宝惠.帕博利珠单抗联合含铂化疗治疗初治的转移性非鳞状NSCLC:KEYNOTE-189的5年结果[J].循证医学,2023,23(4):22-26.
[22] Ham JS, Kim S, Kim HK, et al. Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD 9291treatment[J]. J Thorac Oncol,2016,11(1):1-4.
[23] 侯爱萍.表皮生长因子受体突变非小细胞肺癌靶向药物的研究进展[J].当代医学,2022,28(15):189-194.
[24] SHI Y, ZHANG I, LIU X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer(ICOGEN):a randomised,double-blind phase 3 non-inferiority trial[J]. Lancet Oncol,2013.
[25] Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer:overall survival data from the phaseⅡb LUX-Lung 7 trialpulmo[Z].
[26] Mok TS, CHENG Y, ZHOU X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating[Z].
[27] Soria J C, Ohe Y, Vansteenkiste J, et al. Osimertimib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med,2018,378(2):113-125.
[28] LANKHEET N A, HUITEMA A D, MALLO H, et al.The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome[J]. Eur J Clin Pharmacol, 2013,69(12):2065.
[29] TAKEDA M, OKAMOTO I, NAKAGAWA K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive nonsmall cell lung cancer[J]. Lung Cancer,2015,88(1):74.
[30] ZHANG R X, WU X J, LU S X, et al. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer:a phase II randomized prospective study[J].
[31] 黄灵,马卓.分子靶向抗肿瘤药物的主要不良反应及应对措施[J].湖北科技学院学报(医学版),2018,32(6):90-94.
[32] 谢同济,李研,邢镨元.驱动基因阳性肺腺癌在靶向治疗中病理类型转化的机制与治疗策略[J].中国肺杂志,2020,23(8):701-709.
[33] YUN C H, MENGWASSER K E, TOMS A V, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J]. Proc Natl Acad Sci USA,2008,105(6):2070-2075.
[34] CHABON J J, SIMMONS A D, LOVEJOY A F, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J]. Nat Commun,2016,7(1):118-125.
[35] Katayama R, Khan T M, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK[J]. Proc Natl Acad Sci USA,2011(108).
[36] Choi Y L, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors[J]. N Engl J Med,2010,363(18) :1734-9.
[37] Katayama R, Shaw A T, Khan T M, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers[J]. Sci Transl Med,2012,4(120) :120ra17.
[38] 朱愿超,胡欣,艾斌.肺癌靶向药物耐药机制及处理方案[J].中国临床药理学杂志,2019,35(17):121-125.
[39] Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival[J]. Cancer Cell,2020,15(6):489-500.
[40] Muzumdar MD, Chen PY, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function[J]. Nat Commun, 2017,8(1):1090.
[41] 潘玲.非小细胞肺癌EGFR-TKI耐药机制及治疗策略[J].医学信息,2021,34(7):10-14.